You did everything right. You talked to your doctor, you started the medication, the weight started coming off, and your labs began moving in the direction they were supposed to. And then, somewhere around month three or four, you noticed the drain.
Not a few strands. A tangle. Then more on the pillow, more in the brush, more collecting at your part every time you looked in the mirror under bad lighting. And when you mentioned it, someone (maybe a prescriber, maybe a friend, maybe the internet) told you it was probably nothing. Just stress. Just normal shedding. Just what happens.
It isn't nothing. And you're not imagining it.
For a couple of years, GLP-1-related hair shedding lived mostly in Reddit threads and TikTok comments, which made it easy to dismiss. That's no longer where the evidence sits.
In May 2026, researchers at West Virginia University published the largest analysis of this question to date in Archives of Dermatological Research.1 Using a database of more than 400,000 propensity-matched patients, they compared people starting a GLP-1 with people starting metformin, adjusting for age, sex, obesity, diabetes, smoking, thyroid disease, PCOS, lupus, and pregnancy.
The findings were specific rather than sweeping:
| Medication | Relative risk of new nonscarring hair loss | Significant? |
|---|---|---|
| Semaglutide (Ozempic, Wegovy) | 1.43 (95% CI 1.30 to 1.56) | Yes |
| Tirzepatide (Mounjaro, Zepbound) | 1.68 (95% CI 1.44 to 1.97) | Yes |
| Liraglutide | 1.12 (95% CI 0.93 to 1.37) | No |
| Dulaglutide | 0.94 (95% CI 0.77 to 1.14) | No |
In plain terms: people starting semaglutide were diagnosed with nonscarring hair loss about 43% more often than matched patients on metformin, and people starting tirzepatide about 68% more often.1
This is worth saying plainly: your medication is working, your hair is responding, and both of those things can be true at once. The goal is not to choose between them.
Notice which drugs top that list. The two with a significant signal are also the two that produce the most weight loss. The study authors point to this pattern as the key clue: it suggests the shedding is driven by the weight loss itself rather than by the drug damaging the follicle.1 That distinction matters enormously for what you do next, because a follicle that is resting is a follicle that can be woken up.
What this evidence does not say. This was an observational study, which means it shows an association, not proof of cause. The researchers were not able to measure how much weight each patient actually lost, so the weight-loss explanation is a well-supported hypothesis rather than a proven mechanism. The study also grouped several different types of hair loss together and did not track how long shedding lasted or whether it resolved. Absolute rates stayed low: roughly 0.6% of semaglutide patients received a hair loss diagnosis within a year, versus about 0.45% on metformin.1 A higher relative risk on a small baseline is still a small individual risk.
Your hair grows in a cycle. Most of your follicles, normally around 85 to 90%, sit in anagen, the active growing phase, which can last years. A small percentage are in catagen (a brief transitional shutdown) and telogen (a resting phase of roughly three months), at the end of which the old hair releases and a new one begins pushing up behind it.
Telogen effluvium is what happens when a physiological stressor pushes an abnormally large share of your follicles out of anagen and into telogen all at the same time. They then all release at once, roughly two to four months later. That delay is why the shedding so often feels like it comes out of nowhere. The trigger happened last season, not last week.
Rapid weight loss is a well-established trigger. Here's how a GLP-1 can create several of them simultaneously:
Your body reads a fast, substantial energy deficit as a threat and reallocates resources toward organs that keep you alive. Hair, being biologically expendable, is among the first systems downregulated. This isn't a malfunction. It's triage.
GLP-1s work substantially by suppressing appetite, which means many people are eating meaningfully less food, not just fewer calories. Hair is a protein structure with high metabolic demand, and it's sensitive to shortfalls in protein, iron (measured as ferritin), zinc, vitamin D, and B12. Reviews of this literature specifically flag altered dietary intake and nutritional shortfall as likely contributors.2 If you're eating 900 calories a day because nothing sounds appealing, your follicles will find out before your bloodwork does.
Changes involving insulin and insulin-like growth factor signaling, along with the ordinary stress of managing a chronic condition, may influence androgen activity and the follicle cycle, potentially setting off either telogen effluvium or androgenetic alopecia.2 This is the piece most articles skip, and it's the one that changes prognosis.
This is the important one. If you carry a genetic predisposition to pattern hair loss, you may have had it quietly progressing for years, hidden underneath density you didn't know you were relying on. A telogen effluvium event strips away that buffer. The shedding is temporary, but what it reveals underneath may not be. Many people who "lost their hair on Ozempic" actually lost their camouflage.
Which is exactly why a diagnosis matters more than a supplement.
You are more likely to be dealing with GLP-1-associated shedding, as opposed to something else entirely, if several of these apply:
Signs it may be something in addition to telogen effluvium, and worth a professional look sooner rather than later:
There is no single answer here, because there is no single cause. What follows is roughly the order we work through it at Transitions of Indiana.
This is the step almost everyone skips, and it's the one that saves the most time and money. A scalp and hair analysis with a certified trichologist uses magnified scalp imaging to look at what your follicles are actually doing: density, miniaturization, inflammation, sebum load, and the ratio of growing to resting hairs. That's how we distinguish "this will resolve" from "this has been progressing for six years and the medication just revealed it," which are two completely different treatment paths.
It's also how we know whether to send you back to your primary care provider for labs. Ferritin, TSH and thyroid panel, vitamin D, zinc, and B12 are the standard starting set for diffuse shedding, and they're worth asking for directly.
Ask your provider for: ferritin (not just hemoglobin, since you can have depleted iron stores with normal hemoglobin), a full thyroid panel, vitamin D, zinc, and B12. If you're told your labs are "normal," ask for the actual numbers. "Within range" and "optimal for hair growth" are not the same range.
Protein first. Most people on GLP-1s are under-eating protein without realizing it. A common clinical target is roughly 0.6 to 0.8 grams per pound of goal body weight, but ask your prescriber what's appropriate for you. Prioritize protein at every meal even when appetite is low, and consider whether a registered dietitian should be part of your care team. Many GLP-1 prescribing programs don't include one, and it shows.
A note on biotin, because it's everywhere: biotin supplementation reliably helps only people who are actually biotin-deficient, which is rare. More importantly, high-dose biotin can interfere with common lab assays, including thyroid tests and cardiac troponin, producing misleading results. If you take it, tell whoever draws your blood. Correcting a documented deficiency is worth doing. Taking megadoses on the assumption of one usually isn't.
Once we know what we're treating, several evidence-supported options work well for shedding driven by metabolic stress:
For people whose shedding is prolonged, whose density hasn't recovered, or whose underlying pattern loss has been revealed, we go further:
If your weight has stabilized and the density hasn't returned, that's information, not failure. It usually means genetic pattern loss was underneath all along.
Non-surgical hair replacement delivers immediate, natural-looking density without a procedure, and modern systems are nothing like what the phrase used to mean.
Female hair transplants and male hair transplants relocate follicles that are genetically resistant to loss into thinning areas, for a permanent structural solution.
Not sure what the results actually look like? Our women's gallery and men's gallery are real clients, real timelines.
In most cases, yes. Telogen effluvium is a temporary disruption of the growth cycle, and shedding typically slows within three to six months of the trigger resolving, with visible density returning over six to twelve months. The exception is when the shedding has unmasked underlying pattern hair loss. In that case, the shed hair regrows but the progressive thinning continues. A scalp analysis can tell you which situation you're in.
That's a conversation for your prescriber, not for an article, and not one to act on alone. For most people, the answer is no. The shedding is usually temporary and manageable, while the metabolic benefits are not easily replaced. Adjusting the dose or the rate of weight loss may be an option worth raising with your prescribing provider.
Current evidence leans toward the weight loss. The GLP-1s most strongly linked to hair loss are also the most effective at producing weight loss, and the researchers behind the largest study to date proposed that this pattern fits weight-loss-induced telogen effluvium better than direct damage to the follicle.1 That said, the study could not measure actual weight change, so this remains the leading explanation rather than a settled one.
Typically two to four months. Telogen effluvium is delayed by design. The follicles enter the resting phase when the stressor occurs, then release together at the end of that phase.
This is worth answering carefully, because it is often reported inaccurately. The large majority of people diagnosed with hair loss in the research are women, simply because far more women take these medications for weight management. But when researchers compared like with like, the relative increase in risk was not higher in women. In the 2026 cohort analysis, semaglutide carried a relative risk of 1.58 in men versus 1.37 in women, and tirzepatide 1.83 in men versus 1.68 in women.1
So the honest answer is that women make up most of the cases by volume, while men appear at least as susceptible individually. What is different for women is the experience afterward: women's hair loss presents diffusely rather than in an obvious bald patch, which makes it easier for a provider to under-read at a glance and easier to dismiss as cosmetic.
Often, substantially. Getting a baseline scalp analysis before or early in treatment, protecting protein and micronutrient intake from day one, and starting supportive therapy proactively all improve the odds. Prevention is considerably easier than recovery.
Transitions of Indiana has spent more than 25 years helping people in Indianapolis and across the country understand what's happening with their hair, and what can be done about it. You're allowed to want your health and your hair.
Call us at (317) 871-7330.
Additional background: Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study. Journal of the American Academy of Dermatology. 2025;92(5):1141-1143. doi:10.1016/j.jaad.2025.01.046. Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023. Journal of the European Academy of Dermatology and Venereology. 2025;39(2):e153-e154. doi:10.1111/jdv.20197
Transitions of Indiana. This article is for general education and is not medical advice. Do not start, stop, or change any prescription medication without consulting the provider who prescribed it.
Estimated reading time: 0 minutes
